UBE2D1

Across TCGA pan-cancer cohorts, UBE2D1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of UBE2D1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where UBE2D1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types UBE2D1 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

BLCA, LIHC, and STAD are the cancer types where UBE2D1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UBE2D1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	+0.977	<.001	10	view →
LIHC	All	II,III,IV	+0.832	<.001	9	view →
STAD	All	II,III,IV	+0.873	<.001	8	view →
KIRP	All	II,III,IV	+0.576	.003	8	view →
HNSC	Female	III,IV	+0.784	<.001	7	view →
LUAD	Male	II,III,IV	+0.728	<.001	7	view →
CHOL	Male	All	+1.908	<.001	5	view →
ESCA	All	All	+1.142	.001	4	view →
BRCA	All	II,III,IV	+0.346	<.001	4	view →
KIRC	All	All	+0.258	.001	3	view →
THCA	Female	All	−0.216	.035	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

UBE2D1–BLCA

Open the BLCA breakdown →